Surveillance of adverse events following immunisation in Australia, 2015
Annual report
DOI:
https://doi.org/10.33321/cdi.2017.41.36Keywords:
AEFI, adverse events, vaccines, surveillanceAbstract
This report summarises Australian passive surveillance data for adverse events following immunisation (AEFI) for 2015 reported to the Therapeutic Goods Administration and compares them to long-term trends. There were 2,924 AEFI records for vaccines administered in 2015; an annual AEFI reporting rate of 12.3 per 100,000 population. There was a decline of 7% in the overall AEFI reporting rate in 2015 compared with 2014. This decline in reported adverse events in 2015 compared to the previous year was mainly attributable to fewer reports following the HPV vaccine and replacement of monovalent vaccines (Hib, MenCCV and varicella) with combination vaccines such as Hib–MenC, and MMRV. AEFI reporting rates for most individual vaccines were lower in 2015 compared with 2014. The most commonly reported reactions were injection site reaction (26%), pyrexia (17%), rash (16%), vomiting (8%) and headache (7%). The majority of AEFI reports (85%) were described as non-serious events. There were two deaths reported, but no clear causal relationship with vaccination was found.
Downloads
References
Council for International Organizations of Medical Sciences (CIOMS) c/o World Health Organization. Definition and Application of Terms for Vaccine Pharmacovigilance: Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance. 2012.
Dey A, Wang H, Quinn H, Hill R, Macartney K. Surveillance of adverse events following immunisation in Australia annual report, 2014. Communicable Diseases Intelligence 2016;40:E377–E390.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Surveillance of adverse events following immunisation: Australia 2002 to 2003. Commun Dis Intell 2004;28:324-338.
Lawrence G, Boyd I, McIntyre P, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2005. Commun Dis Intell 2006;30:319-333.
Lawrence G, Gold MS, Hill R, Deeks S, Glasswell A, McIntyre PB. Annual report: surveillance of adverse events following immunisation in Australia, 2007. Commun Dis Intell 2008;32:371-387.
Lawrence G, Menzies R, Burgess M, McIntyre P, Wood N, Boyd I, et al. Surveillance of adverse events following immunisation: Australia, 2000–2002. Commun Dis Intell 2003;27:307-323.
Lawrence GL, Aratchige PE, Boyd I, McIntyre PB, Gold MS. Annual report on surveillance of adverse events following immunisation in Australia, 2006. Commun Dis Intell 2007;31:269-282.
Lawrence GL, Boyd I, McIntyre PB, Isaacs D. Annual report: surveillance of adverse events following immunisation in Australia, 2004 Commun Dis Intell 2005;29:248-262.
Mahajan D, Cook J, Dey A, Macartney K, Menzies R. Supplementary report: surveillance of adverse events following immunisation among children aged less than seven years in Australia, 1 January to 30 June 2012. Commun Dis Intell 2013;37:E130-134.
Mahajan D, Cook J, Dey A, Macartney K, Menzies RI. Annual report: surveillance of adverse events following immunisation in Australia, 2011. Commun Dis Intell 2012;36:E315-332.
Mahajan D, Cook J, McIntyre P, Macartney K, Menzies R. Supplementary report: surveillance of adverse events following immunisation among children aged less than seven years in Australia, 1 January to 30 June 2011. Commun Dis Intell 2012;36:114-119.
Mahajan D, Cook J, McIntyre PB, Macartney K, Menzies RI. Annual report: surveillance of adverse events following immunisation in Australia, 2010. Commun Dis Intell 2011;35:263-280.
Mahajan D, Roomiani I, Gold MS, Lawrence GL, McIntyre PB, Menzies RI. Annual report: surveillance of adverse events following immunisation in Australia, 2009. Commun Dis Intell 2010;34:259-276.
Menzies R, Mahajan D, Gold MS, Roomiani I, McIntyre P, Lawrence G. Annual report: surveillance of adverse events following immunisation in Australia, 2008. Commun Dis Intell 2009;33:365-381.
Mahajan D, Dey A, Cook J, Harvey B, Menzies R, Macartney K. Surveillance of adverse events following immunisation in Australia annual report, 2013. Commun Dis Intell 2015;39:E369–E386.
National Health and Medical Research Council. The Australian Immunisation Handbook. 8th edn. Canberra: Australian Government Department of Health and Ageing; 2003.
National Health and Medical Research Council. The Australian Immunisation Handbook. 9th edn. Canberra: Australian Government Department of Health and Ageing; 2008.
Uppsala Monitoring Centre. WHO Collaborating Centre for International Drug Monitoring. Accessed on 9 July 2014. Available from: http://www.who-umc.org/
Zhou W, Pool V, Iskander JK, English-Bullard R, Ball R, Wise RP, et al. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001. [erratum appears in MMWR Morb Mortal Wkly Rep. 2003 Feb 14;52(06):113]. MMWR Surveill Summ 2003;52:1-24.
Brown EG. Using MedDRA: implications for risk management. Drug Saf 2004;27:591-602.
Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20:109-117.
Mahajan D, Dey A, Hill R, Harvey B, Menzies R, McIntyre P, et al. Methodological framework for reporting of adverse events following immunisation (AEFI) In: PHAA National Immunisation Conference, 17-19 June, 2014; Melbourne, Australia.
Leroy Z, Broder K, Menschik D, Shimabukuro T, D. M. Febrile seizures after 2010-2011 influenza vaccine in young children, United States: a vaccine safety signal from the vaccine adverse event reporting system. Vaccine 2012;30:2020-2023.
Moro PL, Broder K, Zheteyeva Y, Revzina N, Tepper N, Kissin D, et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol 2011;205:e1-9.
Zheteyeva Y, Moro PL, Yue X, K. B. Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol 2013;208:e1-6.
Australian Government Department of Health, Therapeutic Goods Administration. National Adverse Events Following Immunisation (AEFI) reporting form. Accessed on 26 March 2013. Available from: http://www.tga.gov.au/safety/problem-medicine-aefi.htm
SAS Institute Inc. The SAS system for Windows [computer program]. Version 9.4. Cary, N.C. 2012.
Australian Bureau of Statistics. Australian Demographic Statistics. 2015. http://www.abs.gov.au/AUSSTATS/abs@.nsf/DetailsPage/3101.0Jun%202015?OpenDocument#Time
Australian Government Department of Human Services. Australian Immunisation Register. Accessed on 21 October 2016. Available from: https://www.humanservices.gov.au/customer/services/medicare/australian-immunisation-register
Australian Government Department of Health. UPDATE: Expansion of Australia’s Immunisation Registers. Accessed on 21 October 2016. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/67D8681A67167949CA257E2E000EE07D/$File/Factsheet-%20Immunisation-Registers-Expansion-23102015.pdf
Varricchio F, Iskander J, DeStefano F, Ball R, Pless R, Braun M, et al. Understanding vaccine safety information from the Vaccine Adverse Event Reporting System. Pediatr Infect Dis J 2004;23:287-294.
Australian Government Department of Health, Therapeutic Goods Administration. Database of Adverse Event Notifications. Accessed on 26 March 2013. Available from: http://www.tga.gov.au/safety/daen.htm
Simon LS. Pharmacovigilance: towards a better understanding of the benefit to risk ratio. Ann Rheum Dis 2002;61(Suppl II):ii88-89.
Reisinger KS, Block SL, Lazcano-Ponce E, Samakoses R, Esser MT, Erick J, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007;26:201-209.
National Centre for Immunisation Research and Surveillance. AusVaxSafety. http://www.ncirs.edu.au/vaccine-safety/ausvaxsafety/
Pillsbury A, Cashman P, Leeb A, Regan A, Westphal D, Snelling T, et al. Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015. Eurosurveillance 2015; 20:pii=30050.
Mahajan D, Dey A, Cook J, Harvey B, Menzies R, Macartney K. Surveillance of adverse events following immunisation in Australia annual report, 2012. Commun Dis Intell 2014;38:E232– E246.
Immunise Australia. Aboriginal And Torres Strait Islander People. 2015. Accessed on 21 October 2016. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/aboriginal-and-torres-strait-islander-people
Therapeutic Goods Administration. Bexsero meningococcal B vaccine. 2014. Accessed on 23 October 2015. Available from: https://www.tga.gov.au/monitoring-communication/bexsero-meningococcal-b-vaccine
Downloads
Published
How to Cite
License
Copyright (c) 2017 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
